Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study

Abstract

HCT improved OS compared with non-HCT treatment in patients with <i>TP53</i> mutations irrespective of <i>TP53</i> allelic status. Patients with IPSS-M very high risk without a <i>TP53</i> mutation had favorable outcomes when a donor was available.